Top Pharmaceutical Companies in San Francisco Bay Area, CA (140)
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...
GoodRx's Top Stability & Growth Strengths
Product Line Growth: Newer businesses such as Pharma Direct and subscriptions are expanding rapidly, with clear momentum highlighted in 2026. Investment is being shifted toward these lines to replace slower legacy revenue.
Future-Ready Strategy: Management is prioritizing Pharma Direct and subscription products and raised 2026 revenue guidance, signaling a transition aimed at restoring overall growth. These segments are described as the main engines expected to offset declines in the legacy business.
Profitability: Profitability remains solid even as the top line fluctuates, including positive GAAP earnings and substantial adjusted EBITDA in Q2 2026. Operating cash flow also strengthened, supporting continued execution.
Summit Mission Statement: To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, as well as successful commercialization of patient, physician, caregiver, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs. To identify and control promising...
Herbaland Naturals Inc. is a Canadian family-owned natural health and wellness brand founded in 2009. As Canada's largest nutritional gummy manufacturer, it produces over 70 million vitamins, supplements, and functional snacks annually. Its mission is to bring health and wellness to everyone by creating natural health products that are functional, sustainable, and environmentally friendly, while ensuring prosperity for its employees.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as NASH, obesity and cancer. Terns’ pipeline includes four clinical stage development programs including a THR-β agonist, an allosteric BCR-ABL inhibitor, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program. For more...
Advancing market-access marketing through experiential strategy, effective value demonstration, and market-access-focused resource development. The value of innovative medical treatments often begins with an evaluation of cost. As former payers ourselves, we know. So we identify and assess evidence of economic, clinical, and humanistic value, then analyze it to effectively demonstrate the total value of medical innovations—and maximize commercial success.
Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach...
Seranova Bio is a biotechnology company developing therapeutics from naturally occurring protective autoantibodies. Its REAP platform profiles these antibodies and links their activity to clinical outcomes, helping identify human-supported therapeutic targets and understand disease biology. The company applies this approach to drug discovery across areas including autoimmunity, oncology, and neurodegeneration, with the goal of advancing first-in-class therapies inspired by patient...
Nosis Bio is an AI-native biotechnology company pioneering receptor-targeted RNA therapeutics. They leverage deep learning and novel biochemistry to develop cell-specific RNA medicines, aiming to solve drug delivery challenges and create programmable therapeutics.
PSI is a leading full-service global Contract Research Organization whose key strength is predictable patient enrollment across multiple therapeutic areas. PSI is known in the industry as a CRO focused on ‘on-time project delivery’. This is achieved through investing substantial effort and MD resources into performing quality feasibility assessments that provide an accurate predictor of study timelines. PSI’s global reach allows us...
Drug Hunter™ is an essential subscription service for R&D-focused organizations turning molecules into medicines. Every day, drug discovery strategies, tactics, challenges and solutions are disclosed, but the knowledge is fragmented across journals, conferences, patents, databases, news, company reports, filings and endless other sources, making it challenging to find and apply. Drug Hunter’s experts keep you current by connecting the dots, distilling industry...
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with...
Roche's Top Stability & Growth Strengths
Strong Market Position & Advantage: Roche is the global leader in in‑vitro diagnostics and remains a top‑tier biopharma with a significant oncology footprint. The dual Pharmaceuticals–Diagnostics model is a strategic differentiator at scale.
Strong Revenue Growth: Group sales rose 7% at constant exchange rates in 2025 and 6% at CER in Q1 2026, with both divisions contributing. Guidance for 2026 indicates continued mid–single‑digit CER growth.
Profitability: Profitability improved in 2025 alongside sales, with higher IFRS net income and core EPS growth. Management pointed to capacity to keep investing while rewarding shareholders.
ImmunEdge is a biopharmaceutical company committed to developing novel therapeutics for patients with serious or life-threatening diseases. With a highly experienced team of experts in immunology and drug development, we are pioneering innovative approaches to target and modulate key molecular pathways that regulate the immune response.
We’re excited to share Alexza’s new corporate identity. It’s a brand that expresses our evolution and brings us closer to Ferrer, our parent company since 2016. We’re moving forward and, at the same time, staying true to our objective of offering high-quality pharmaceutical products for the acute treatment of disease, in order to make a positive impact in society. We...
Biolog, Inc. is a biotechnology company that designs and develops cell-based phenotypic testing technologies, cellular assays, and microbial identification systems. They provide tools and services for microbial characterization and identification to pharmaceutical, food and beverage, industrial, and agricultural organizations.
Menten AI pioneers generative AI to design cyclic peptide therapeutics and protein drugs/enzymes for therapeutic and industrial purposes, utilizing machine learning, quantum computing, and physics-based models.
Valo is a technology company built to transform the drug discovery and development process using human-centric data and AI-powered computation. Valo is fully integrating human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company’s Opal Computational Platform™...
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of...
Ashfield Advisory is a business unit that provides integrated advisory and consulting services to the healthcare industry, leveraging an ecosystem of specialized businesses for insight, strategy, and action.
There are two Otsuka pharmaceutical industry companies in the U.S.: Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis.
Otsuka America Pharmaceutical's Top Stability & Growth Strengths
Strong Revenue Growth: Recent disclosures indicate double-digit growth at the parent level with North America identified as the largest and expanding region. Management attributes momentum to U.S.-marketed medicines such as REXULTI, ABILIFY MAINTENA, and JYNARQUE powering the pharmaceutical segment.
Strong Market Position & Advantage: The company is repeatedly portrayed as a leader in mental health and nephrology, supported by first-in-class and category-defining therapies. Flagship assets like aripiprazole long-acting injectables, REXULTI’s Alzheimer’s agitation indication, and JYNARQUE underpin durable positioning in core niches.
Innovation-Driven Growth: Multiple approvals, priority reviews, and acquisitions underscore an active pipeline across CNS and renal diseases. Examples include FDA priority review for centanafadine, accelerated approval for sibeprenlimab, digital therapeutic launches, and targeted deals to strengthen U.S. capabilities.
Partnering to Advance Human Health A unique culture delivering exceptional solutions: Almac is a financially secure, privately owned organisation with 7,500 employees globally. 600+ companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 50 years. Our vast range of services include: Biomarker Discovery & Development: Pre-clinical...



































